FDA 483 - Martin Kankam - December 16, 2016

An FDA inspection of Martin Kankam, a clinical investigator in Overland Park, Kansas, revealed a significant issue with a clinical study. The firm failed to conduct an investigation in accordance with the investigational plan, specifically regarding incorrect dosing of subjects in a drug immunogenicity study. This indicates a serious deviation from study protocol.